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Between January 2001 and December 2005, 117 patients with infective
endocarditis on native valves were operated in the active phase of the disease.
The average age of our patients was 40.32 years with a male ascendancy. The
causal heart disorder was found in 89% of the cases, dominated by rheumatoid
arthritis. The germ in cause was isolated in 52.7% of the cases. The operative
indication was hemodynamic in 60 cases, infectious in 14 cases, prosthetic
valve endocarditis with severe prosthetic dysfunction and embolic in 18 cases.
The average operating delay was of 16.38±16.88 days with regard to the
beginning of the antibiotic treatment. We realized valvular aortic replacement
at31 patients with reconstruction of the ring in ten cases, a valvular mitral
replacement at 35 patients, a mitroaortic replacement at 20 patients, a recon-
structive mitral surgery in 26 cases, and a reconstructive tricuspid surgery in
five cases. 
The early mortality was 20.5%. The follow-up was 89% with an average
recession of 3.1 years and a late mortality of 7%. The aim of this study is to
analyze the immediate and late results of the surgery of infective endocarditis
in the active phase and to bring to light the prognostic factors of mortality.
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It is unknown if patients who developed symptomatic mitral restenosis
after PMV may benefit from repeat percutaneous mitral balloon valvuloplasty
(PMV). Our purpose is to assess the immediate and long-term outcomes of
repeat PMV for post-PMV mitral restenosis.
We report the immediate outcomes and long-term clinical follow-up results
of 73 patients (mean age 29,95 years, 80,6% women) with symptomatic mitral
restenosis after prior PMV, who were treated with a repeat PMV at 51,73±29,4
months after the initial PMV. The mean follow-up period was 58, 85 months .
There was a significant increase in the mitral valve area (1,08±0,21 to
1,76±0,32; p<0,001), and decrease in the mean transmitral gradient
(15,28±6,84 to 8,67±4,07 mm Hg; p<0.001) and the mean left atrial pressure
(25,01±7,33 to 14,75±5,88 mm Hg; p<0,001). Mean pulmonary artery pres-
sure decreases significantly with redo PMV (47,5±14,73 to 34,38±9,57;
p<0,001).
The onset of new mitral regurgitation had occurred in 15 patients (21, 7%)
Successful procedural outcome was achieved in 79, 6% of patients. No patient
developed severe mitral regurgitation after redo PMV.
There were no in-hospital complications. Early symptomatic improvement
after redo PMV of 1 NYHA functional class was obtained in 96.7% of the
patients. During the follow-up period, there were no deaths, and 10 (13, 69%)
patients required mitral valve replacement.
Overall, 44 patients (60, 27%) were alive without further valvular interven-
tion at follow up after redo PVM. All of these patients were in NYHA class I
or II at follow-up. The probability of event-free survival (alive and free of
mitral valve replacement and/or NYHA class >III) at follow up was 91.2%.
By univariate analysis age, history of previous surgical commissurotomy,
pre-PMV NYHA functional class, lower echocardiographic score, post-PMV
pulmonary artery pressure and atrial fibrillation were identified as univariate
predictors of long-term event-free survival in the redo PMV group.
Repeat percutaneous mitral valvuloplasty in patients with restenosis after a
prior percutaneous valvuloplasty is feasible and can be accomplished with
acceptable morbidity and mortality. 
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Introduction:
 
 The percutaneous balloon mitral valvuloplasty (PBMV)
became the procedure of choice of the mitral stenosis with favorable mor-
phology. The development of the pulmonary hypertension (PH) is a frequent
in patients with mitral stenosis. However, its influence on results of the PBMV
is unknown. 
 
Aim:
 
 To determine the impact of the PH on immediate and long term
results of the PBMV. 
 
Patients and methods:
 
 Retrospective study that spreads on 6 years (from
1996 to 2002) regrouping all patients having undergone a PBMV for the first
time. Clinics, echographic, hemodynamic data of patients have been collected.
72 patient had a systolic arterial pulmonary pressure (SPP) 60 mmHg (group
H) whereas 217 had a SPP <60 mmHg (group N). 
 
Results: 
 
Group H patients were older, had more acute pulmonary edema at
admission, an echographic score >8, tricuspid regurgitation and smaller pre
PBMV mitral surface. A bad result was noted in 11.4% in group H against
8.6% in group N (p=0, 04). Post procedural complications were similar, except
for the severe mitral regurgitation, more often frequent in the group H. During
a mean follow-up of 92 months, fifty-three patients in group H and 204
patients in group N were free of cardiac events. The NYHA class I or II were
met more in the N group. The residual systolic pulmonary pressure was higher
in H group.
 
Conclusion:
 
 The PBMV is an efficient procedure even in presence of PH
in spite of the pejorative character that it confers on the immediate and long-
term prognosis.
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Background:
 
 Although trans aortic valve implantation (TAVI) is a prom-
ising alternative solution for patients who could not undergo conventional sur-
gery, few data are available regarding post-procedure complications among
these fragile subjects
 
Objectives:
 
 We sought to evaluate the factors associated with adverse out-
come in patients with TAVI.
 
Methods:
 
 Clinical, biological and echocardiographic characteristics of the
patients were assessed before implantation.Patients were followed up to 30
days after procedure. Our main primary end-point was the composite of
death+stroke+acute pulmonary edema at day 30.
 
Results:
 
 Between November 2008 and March 2010, n=55 patients under-
went TAVI in our institution (mean age=84.4±0.7 y; 40% men; mean STS
score=25.2±1.3; 65% transfemoral). Primary endpoint occured in n=9 subjects
(n=2 deaths; n=1 stroke; n=6 pulmonary edema), who presented a longer in-
hospital stay (14.4±3.2 vs. 9.2±0.6 days, p=0.008).
Patients experiencing the primary endpoint were comparable to the others
in terms of age, gender, renal function, comorbidities, type of percutaneous
